Mahamaya Lifesciences IPO 2025| SME IPO 2025| Agrochemical IPO| Pesticide Industry India| BSE SME listing| IPO allotment 2025
🌿 Introduction
Mahamaya Lifesciences Ltd, a Delhi-based agrochemical formulation manufacturer, is all set to launch its SME IPO worth ₹70.44 crore on the BSE SME platform. The IPO opens on 11 November 2025 and closes on 13 November 2025, with a tentative listing date of 18 November 2025.
This IPO aims to fund the company’s manufacturing expansion, technical plant setup, warehouse construction, and working capital requirements.
Mahamaya Lifesciences, incorporated in 2002 and converted into a public limited company in 2024, specializes in pesticide formulations and technical-grade molecules. With increasing demand in the Indian agrochemical sector, this IPO has attracted attention from both retail and institutional investors.
📊 Mahamaya Lifesciences Ltd IPO Details
| Particulars | Details |
|---|---|
| IPO Type | Book Building (SME IPO – BSE SME) |
| Issue Size | ₹66.73 crore – ₹70.44 crore |
| Price Band | ₹108 – ₹114 per share |
| Face Value | ₹10 per share |
| Lot Size | 2,400 shares |
| Minimum Investment (Retail) | ₹2,59,200 – ₹2,73,600 |
| Issue Opens | 11 November 2025 |
| Issue Closes | 13 November 2025 |
| Listing Date | 18 November 2025 |
| Lead Manager | Gretex Corporate Services Ltd |
| Registrar | Bigshare Services Pvt Ltd |
| Exchange | BSE SME |
🏭 Company Overview
Mahamaya Lifesciences Ltd is a manufacturer of pesticide formulations catering to both Indian agrochemical companies and global players. Its primary focus lies in developing new pesticide molecules, bulk formulations, and technical-grade chemicals that address the evolving agricultural needs of India.
- Headquarters: New Delhi
- Incorporation Year: 2002
- Promoters: Mr. Krishnamurthy Ganesan, Mrs. Lalitha Krishnamurthy, and Mr. Prashant Krishnamurthy
The company aims to strengthen India’s self-reliance in agrochemicals by producing molecules that are not yet manufactured domestically.
💰 Objects of the Issue
The IPO proceeds will be primarily used for:
- Setting up a new technical manufacturing plant for pesticide molecules
- Purchase of equipment and machinery for the existing formulation facility
- Construction of warehouse and storage infrastructure
- Working capital and general corporate purposes
This expansion will enhance Mahamaya’s capacity to meet both domestic and export demands for crop protection products.
📈 Financial Performance Snapshot
| Financial Year | Revenue (₹ crore) | PAT (₹ crore) |
|---|---|---|
| FY 2023 | 137.39 | 3.73 |
| FY 2024 | 162.82 | 5.47 |
The company reported a CAGR of 18% in revenue over the last two years, with improving profitability as it expands its product portfolio.
While the profit margins are moderate (~3%), the fresh investment in plant and machinery is expected to push future margins higher.
🌾 Industry Outlook
The Indian agrochemical industry is valued at over ₹75,000 crore and is expected to grow at 8–10% CAGR driven by:
- Rising population and food security demand
- Limited arable land requiring higher crop yield
- Government incentives for “Make in India” manufacturing
- Increasing exports of generic pesticide formulations
Mahamaya Lifesciences, with its technical manufacturing expansion, is positioned to benefit from this sectoral growth.
🔍 Strengths of Mahamaya Lifesciences
✅ Experienced Promoters – Over two decades of expertise in agrochemicals and formulation technology.
✅ Diverse Product Portfolio – Focus on pesticide, insecticide, and herbicide formulations, catering to multiple crop categories.
✅ Upcoming Technical Manufacturing Plant – Backward integration expected to enhance profit margins and reduce dependency on imports.
✅ Strong Customer Base – Supplies to both Indian agrochemical companies and MNCs.
✅ Growth Aligned with Sectoral Trends – Rising demand for eco-friendly and efficient crop protection solutions.
⚠️ Key Risks and Challenges
🚫 SME Segment Risk: Limited post-listing liquidity; share price can be volatile.
🚫 Execution Risk: Timely completion of the new plant and warehouse is critical for achieving projected growth.
🚫 Regulatory Risk: Agrochemical regulations are stringent; any change in pesticide bans or registration could impact operations.
🚫 Working Capital Intensive: The business relies on high inventory and credit cycles typical of agrochemicals.
🚫 Competition: Faces competition from established players like UPL, Rallis India, and Bharat Rasayan.
💡 Valuation Insights
At the upper price band of ₹114, Mahamaya Lifesciences’ post-issue P/E ratio is expected around 20–22x based on FY24 earnings — moderate for SME listings but higher compared to peers like Aimtron Electronics or Rocking Deals that listed earlier in 2025.
Given its expansion plans and rising margins, it could justify a premium if revenue sustains growth in FY26–27.
However, investors must factor in SME-specific risks — limited float, higher volatility, and potential low post-listing liquidity.
📆 Important Dates
- IPO Opening Date: 11 November 2025
- IPO Closing Date: 13 November 2025
- Allotment Finalization: 14 November 2025
- Refund Initiation: 15 November 2025
- Shares Credit to Demat: 17 November 2025
- Listing Date: 18 November 2025
💸 Retail Investor Strategy
For retail investors, Mahamaya Lifesciences IPO presents a niche agrochemical play with long-term growth potential, but it is not without risk.
Recommended Approach:
- ✅ Apply only if you have high-risk appetite and can hold post-listing.
- ✅ Focus on long-term gains rather than listing-day profit booking.
- ⚠️ Minimum investment of ₹2.7 lakh makes it suitable for HNIs or serious SME investors.
- ⚠️ Avoid over-allocation given the liquidity constraints in SME space.
🧭 Expert Outlook
Analysts view Mahamaya Lifesciences as a moderate-risk, sectoral growth IPO. The expansion plan aligns with the “Make in India” narrative and offers potential upside over 2–3 years.
However, short-term volatility post-listing is expected. The GMP (grey market premium) trend closer to issue opening will provide a clearer signal of market sentiment.
Suzlon Energy Q2 FY26 Results: Profit Surges 538% YoY, Strong Wind Order-book Fuels Growth
🏁 Conclusion
Mahamaya Lifesciences Ltd’s IPO combines sectoral tailwinds, expansion-driven growth, and experienced promoters, making it an intriguing SME opportunity.
Yet, it comes with execution, liquidity, and valuation risks typical of SME IPOs.
Verdict: 🌟 Moderate Subscribe for Long-Term Investors
(Investors with risk appetite and belief in India’s agrochemical growth story may consider small exposure.)
Mahamaya Lifesciences IPO 2025| SME IPO 2025| Agrochemical IPO| Pesticide Industry India| BSE SME listing| IPO allotment 2025
Subscription:
| Date | Anchor | QIB | NII | BNII(>10l) | SNII(<10L) | Retail | Total |
|---|---|---|---|---|---|---|---|
| Day-1 | 1 | 0.00 | 0.35 | 0.53 | 0.00 | 0.07 | 0.11 |
| Day-2 | 1 | 0.65 | 0.27 | 0.37 | 0.08 | 0.20 | 0.34 |
| Day-3 | 1 | 1.19 | 3.63 | 5.00 | 0.90 | 1.02 | 1.63 |
GMP Trend:
| Date | GMP |
|---|---|
| 11 Nov 2025 | ₹0.00(0.00%) |
| 12 Nov 2025 | ₹0.00(0.00%) |
| 13 Nov 2025 | ₹0.00(0.00%) |
It should be noted that IPO GMP is subject to extreme volatility, so an investment decision based solely on Patel Retail IPO GMP will prove risky. Therefore, before to investing, consider all factors and make the right investment decision whether to invest in Patel Retail IPO or not.
📢 Join Our Market Community
📱 Stay updated on IPOs, Results & Market News:
- WhatsApp Channel: Join Now
- Telegram: Follow Updates
- Arattai: Connect with Us
How to Check IPO Allotment Status:
Maashitla Securities
To check IPO allotment status, follow the steps below:
- Click on the below allotment status check button.
- Select Company Name.
- Enter your PAN Number, Application Number or DP Client ID (Anyone).
- Click on Search.
NSE Website
To check IPO allotment status, follow the steps below:
- Click on the below allotment status check button.
- Select Company Name.
- Enter your PAN Number, Application Number or DP Client ID (Anyone).
- Click on Search.
BSE Webiste
To check IPO allotment status, follow the steps below:
- Click on the below allotment status check button.
- Select Company Name.
- Enter your PAN Number, Application Number or DP Client ID (Anyone).
- Click on Search.
📌 Stock Market Disclaimer
- Disclaimer: This post is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy/sell any stock or share. Investing in the stock market involves risk. Past performance is not indicative of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.
- The information provided on this platform is for educational and informational purposes only. It should not be considered as investment advice, stock recommendations, or financial guidance.
- ⚠️ Stock Market Investments
- Investing in equities, derivatives, mutual funds, and other financial instruments involves market risks, volatility, and the possibility of capital loss.
- Past performance of stocks or indices is not indicative of future returns.
- Always conduct your own research or consult a SEBI-registered financial advisor before making investment decisions.
- ⚠️ IPO (Initial Public Offerings)
- IPO details, issue size, subscription data, and allotment status shared here are based on publicly available information from company filings, stock exchanges, and merchant bankers.
- Investing in IPOs carries risks including listing volatility, business uncertainties, and sector performance dependency.
- Neither acceptance of applications nor allotment guarantees profits. Investors should evaluate their risk appetite before subscribing.
- ⚠️ GMP (Grey Market Premium)
- Grey Market Premium (GMP) is an unofficial and unregulated indicator of expected IPO listing price.
- GMP data is collected from market observers and informal trading circles; it does not have any legal or SEBI recognition.
- GMP values are highly speculative and may differ significantly from actual listing prices. Investors should not rely solely on GMP while taking investment decisions.
- ✅ General Advisory
- We do not provide any buy/sell/hold recommendations.
- Readers and investors are solely responsible for their investment actions and decisions.
- This platform, its authors, and affiliates are not liable for any direct or indirect financial loss arising from the use of this information.
- 🔒 Always invest responsibly and diversify your portfolio.
Open Demat Account
by Mirae Asset (m,Stock)
-
Indian Stock Market Today: Full Analysis + Tomorrow Outlook
Nifty Market Analysis Today| Bank Nifty Prediction| Fin Nifty Levels| Midcap Market Outlook| Indian Stock Market Today 📌 Index Performance…
-
Cloudflare Global Outage: What Happened and How It Impacted the World & India
Cloudflare Outage 2025| Cloudflare Outage| Cloudflare Down| Website Outage| CDN Issue| India Internet Issue| Global Internet Outage| DNS Failure| Tech…
